Xenon Pharmaceuticals XENE Balance Sheet Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $545.87M+174% | $199.16M+90.6% | $104.51M-22.8% | $135.38M+16.1% | $116.66M-18.3% | ||
| $548.88M+56.9% | $349.72M-2.2% | $357.75M+1.6% | $352.16M-18.7% | $432.97M-10.6% | ||
| $1.11B+97.4% | $560.65M+16.8% | $480.14M-4.0% | $500.25M-11.5% | $565.54M-11.0% | ||
| $8.29M-4.9% | $8.72M-1.9% | $8.89M-3.5% | $9.21M-5.1% | $9.7M-5.7% | ||
| $1.39B+119% | $633.16M+4.2% | $607.84M-9.9% | $674.28M-9.3% | $743.28M-6.9% | ||
| $38.25M-5.0% | $40.26M+9.3% | $36.84M+16.6% | $31.59M+3.1% | $30.65M-10.4% | ||
| $39.82M-4.7% | $41.79M+9.0% | $38.34M+16.0% | $33.05M+3.2% | $32.03M-10.0% | ||
| $48.99M-4.7% | $51.4M+6.4% | $48.33M+19.9% | $40.3M+2.5% | $39.32M-9.1% | ||
| $2.42B+51.5% | $1.6B+8.4% | $1.48B+0.4% | $1.47B+0.6% | $1.46B+0.3% | ||
| -$1.35B-8.2% | -$1.25B-9.2% | -$1.14B-8.7% | -$1.05B-8.8% | -$964.52M-7.2% | ||
| $1.34B+130% | $581.76M+4.0% | $559.51M-11.7% | $633.98M-9.9% | $703.96M-6.7% | ||
| $1.39B+119% | $633.16M+4.2% | $607.84M-9.9% | $674.28M-9.3% | $743.28M-6.9% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Xenon Pharmaceuticals's total assets?
- Xenon Pharmaceuticals (XENE) holds $1.4B in total assets, up 86.6% year over year.
- How much debt does Xenon Pharmaceuticals have?
- Xenon Pharmaceuticals carries $7.5M in total debt against $1.3B of shareholders' equity, a debt-to-equity ratio of 0.01.
- How much cash does Xenon Pharmaceuticals have?
- Xenon Pharmaceuticals holds $545.9M in cash and equivalents.
- Can Xenon Pharmaceuticals cover its short-term obligations?
- Its current ratio is 27.79 — current assets exceed current liabilities.
- Where does Xenon Pharmaceuticals's balance sheet data come from?
- Every line is extracted from Xenon Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.